Laboratory Considerations for Clinical Trials
Science:Life Sciences
In this episode, Dr. Wayne Hogrefe and Dr. Pat Hurban discuss the use of NGS in the development and assessment of new vaccines against the influenza virus.
Topics covered include:
- What health organizations are looking for that drives the selection of the next season's vaccine strains
- How sequence data is used to evaluate the effectiveness of a vaccine while providing insight into the evolution of the virus
- How the sequence data can inform the development of new types of vaccines and therapeutics
- The prospects for a vaccine that is effective across multiple strains and multiple seasons
- How NGS data differs from traditional Sanger sequencing data and what can be learned from that
You can learn more about this topic at www.q2labsolutions.com
More Episodes
What is the Role of Digital Pathology in Clinical Trials
2023-11-17
200
2023-11-17
200
Flexible Approaches for Biotech Companies in Clinical Trials
2022-06-22
284
2022-06-22
284
Risk Management for Biotech Companies in Clinical Trials
2022-05-16
216
2022-05-16
216
Managing Sample Data from Vendors
2021-09-14
248
2021-09-14
248
Automation within an ADME Laboratory
2021-08-26
209
2021-08-26
209
Bioanalytical Automation of Samples
2021-07-30
183
2021-07-30
183
Consent Tracking for Clinical Samples
2021-07-28
185
2021-07-28
185
Tracking Clinical Trial Samples
2021-07-28
178
2021-07-28
178
Avoiding Canceled Tests in Pediatric Samples
2021-02-02
145
2021-02-02
145
Covid Vaccine Testing
2020-09-15
195
2020-09-15
195
Hybrid Assays for Protein Bioanalysis
2020-07-29
157
2020-07-29
157
High Throughput ADME Testing
2020-07-29
99
2020-07-29
99
Liquid Biopsy Collection in Clinical Development Programs
2020-07-29
145
2020-07-29
145
Get this podcast on your
phone, FREE
